For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenues | - | - | - | 26 |
| General and administrative | 229 | 314 | 351 | 351 |
| Transaction expenses | 1,075 | 1,219 | - | - |
| Total operating expenses | 1,304 | 1,533 | 351 | 351 |
| Operating loss | -1,304 | -1,533 | -351 | -325 |
| Interest and dividend income | 496 | 501 | 654 | 605 |
| (loss) income before income (expense) benefit | -808 | -1,032 | 303 | 280 |
| Income tax (expense) benefit | 16 | -42 | 49 | 4 |
| Net (loss) income | -824 | -990 | 254 | 276 |
| Accretion of dividend on series c preferred stock | 531 | 531 | 531 | 531 |
| Net loss available to common shareholders | -1,355 | -1,521 | -277 | -255 |
| Earnings per share, basic | -0.02 | -0.02 | 0 | 0 |
| Earnings per share, diluted | 74,215,000 | 74,215,000 | 74,215,000 | 74,215,000 |
| Weighted average number of shares outstanding, basic | 74,215,000 | 74,215,000 | 74,215,000 | 74,215,000 |
| Weighted average number of shares outstanding, diluted | -0.02 | -0.02 | 0 | 0 |
ENZON PHARMACEUTICALS, INC. (ENZN)
ENZON PHARMACEUTICALS, INC. (ENZN)